Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada ...

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk India Pvt Ltd (NNIPL) and the Indian Institute of Management Ahmedabad (IIMA) have signed a Memorandum of ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Novo Nordisk A/S (NYSE:NVO) is one of the 11 Best Foreign Stocks to Buy According to Hedge Funds. On June 18, TD Cowen ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Collaboration aims to develop model clinics and strengthen capacity of healthcare professionals in management of obesity ...